Table 1 Characteristics of participants. Age is described as mean and standard deviation
No. | Study | Group | Total number of randomized patients | Age | TBSA (%) of patients to be included | Country | Socio-demographics |
|---|---|---|---|---|---|---|---|
1 | Williams 2011 [29] | Propranolol | 125 | 7 (5) | Burns >30% | USA | Not described |
Standard care | 215 | 8 (5) | |||||
2 | W Norbury 2007 [28] | Propranolol | 33 | Not described | Burns >40% | USA | Not described |
Standard care | 33 | Not described | |||||
3 | Wurzer 2015 [30] | Propranolol | 43 | Not described | Burns >30% | USA | Not described |
Standard care | 39 | ||||||
4 | Ali 2014 [21] | Propranolol | 21 | Not described | Burns >30% | USA | Not described |
Standard care | 21 | ||||||
5 | Komak 2012 [26] | Propranolol | 29 | Not described | Burns >40% | USA | Not described |
Standard care | 35 | ||||||
6 | Ali 2015 [22] | Propranolol | 35 | 41 (14) | Burns >30% | USA | Not described |
Standard care | 34 | 38 (16) | |||||
7 | Herndon 2012 [24] | Propranolol | 90 | 7 (5) | Burns >30% | USA | Majority of participants were Hispanic: 97% in the control group and 91% in the propranolol group |
Standard care | 89 | 7 (5) | |||||
8 | Akbar Mohammadi 2009 [27] | Propranolol | 37 | 27.21 (9.73) | Burns 20–50% | Iran | Not described |
Standard care | 42 | 24.54 (12.06) | |||||
9 | Jeschke 2007 [25] | Propranolol | 102 | 7.2 (0.6) | Burns >40% | USA | Not described |
Standard care | 143 | 7.8 (0.4) | |||||
10 | Herndon 2001 [23] | Propranolol | 12 | 6.6 (1.5) | Burns >40% | USA | Not described |
Standard care | 12 | 7.8 (1.4) |